Eniluracil
- Generic Name
- Eniluracil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H4N2O2
- CAS Number
- 59989-18-3
- Unique Ingredient Identifier
- 2E2W0W5XIU
- Background
Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a variety of cancers including colorectal, br...
- Indication
For the treatment of cancer in combination with 5-fluorouracil.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- Adherex Technologies, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT01231802
- Locations
- 🇷🇺
Chelyabinsk Regional Clinical Oncology, Chelyabinsk, Russian Federation
🇷🇺Republic Oncology Center, Republic of Karelia, Russian Federation
🇷🇺Stavropol Regional Clinical Oncology Center, Stavropol, Russian Federation
Eniluracil Hand Foot Syndrome
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 3
- Registration Number
- NCT00827580
- Locations
- 🇺🇸
Clinical Trials Research Unit, West Virginia University, Morgantown, West Virginia, United States
Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-09-16
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 28
- Registration Number
- NCT00004195
Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 950
- Registration Number
- NCT00003873
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.